CDK Inhibitors: Cell Cycle Regulators and Beyond

Developmental Cell

Volumn 14, Issue 2, 2008, Pages 159-169

  Besson, Arnaud ^a   Dowdy, Steven F ^b   Roberts, James M ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLINE; ONCOPROTEIN; PROTEIN P21; PROTEIN P27; RHO FACTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE REGULATION; CELL FATE; CELL METABOLISM; CELL MIGRATION; CELLULAR DISTRIBUTION; CYTOSKELETON; EMBRYO DEVELOPMENT; GROWTH INHIBITION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYTOSKELETON; GENE EXPRESSION REGULATION; HUMANS; TUMOR SUPPRESSOR PROTEINS;

EID: 38849187293     PISSN: 15345807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.devcel.2008.01.013     Document Type: Review

References (143)

1. Adkins J.N., and Lumb K.J. Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2. Proteins 46 (2002) 1-7
2. Alt J.R., Gladden A.B., and Diehl J.A. p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J. Biol. Chem. 277 (2002) 8517-8523
3. Andrews S.C., Wood M.D., Tunster S.J., Barton S.C., Surani M.A., and John R.M. Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7. BMC Dev. Biol. 7 (2007) 53
4. Besson A., Assoian R.K., and Roberts J.M. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?. Nat. Rev. Cancer 4 (2004) 948-955
5. Besson A., Gurian-West M., Schmidt A., Hall A., and Roberts J.M. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 18 (2004) 862-876
6. Besson A., Gurian-West M., Chen X., Kelly-Spratt K.S., Kemp C.J., and Roberts J.M. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 20 (2006) 47-64
7. Besson A., Hwang H.C., Donovan S.L., Cicero S., Gurian-West M., Johnson D., Clurman B.E., Dyer M.A., and Roberts J.M. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 21 (2007) 1731-1746
8. Bhuiyan Z.A., Yatsuki H., Sasaguri T., Joh K., Soejima H., Zhu X., Hatada I., Morisaki H., Morisaki T., and Mukai T. Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome. Hum. Genet. 104 (1999) 205-210
9. Biankin A.V., Kench J.G., Morey A.L., Lee C.S., Biankin S.A., Head D.R., Hugh T.B., Henshall S.M., and Sutherland R.L. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res. 61 (2001) 8830-8837
10. Blain S.W., Scher H.I., Cordon-Cardo C., and Koff A. p27 as a target for cancer therapeutics. Cancer Cell 3 (2003) 111-115
11. Blint E., Phillips A.C., Kozlov S., Stewart C.L., and Vousden K.H. Induction of p57(KIP2) expression by p73β. Proc. Natl. Acad. Sci. USA 99 (2002) 3529-3534
12. Borriello A., Cucciolla V., Oliva A., Zappia V., and Della Ragione F. p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle 6 (2007) 1053-1061
13. Butty A.C., Pryciak P.M., Huang L.S., Herskowitz I., and Peter M. The role of Far1p in linking the heterotrimeric G protein to polarity establishment proteins during yeast mating. Science 282 (1998) 1511-1516
14. Canela N., Rodriguez-Vilarrupla A., Estanyol J.M., Diaz C., Pujol M.J., Agell N., and Bachs O. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J. Biol. Chem. 278 (2003) 1158-1164
15. Chang T.S., Kim M.J., Ryoo K., Park J., Eom S.J., Shim J., Nakayama K.I., Nakayama K., Tomita M., Takahashi K., et al. p57KIP2 modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein Kinase. J. Biol. Chem. 278 (2003) 48092-48098
16. Cheng M., Sexl V., Sherr C.J., and Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA 95 (1998) 1091-1096
17. Child E.S., and Mann D.J. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 5 (2006) 1313-1319
18. Chu I., Sun J., Arnaout A., Kahn H., Hanna W., Narod S., Sun P., Tan C.K., Hengst L., and Slingerland J. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128 (2007) 281-294
19. Coats S., Flanagan W.M., Nourse J., and Roberts J.M. Requirements of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272 (1996) 877-880
20. Collins L.R., Ricketts W.A., Yeh L., and Cheresh D. Bifurcation of cell migratory and proliferative signaling by the adaptor protein Shc. J. Cell Biol. 147 (1999) 1561-1568
21. Connor M.K., Kotchetkov R., Cariou S., Resch A., Lupetti R., Beniston R.G., Melchior F., Hengst L., and Slingerland J.M. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol. Biol. Cell 14 (2003) 201-213
22. Coqueret O., and Gascan H. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J. Biol. Chem. 275 (2000) 18794-18800
23. Dash B.C., and El-Deiry W.S. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol. Cell. Biol. 25 (2005) 3364-3387
24. De la Cueva E., Garcia-Cao I., Herranz M., Lopez P., Garcia-Palencia P., Flores J.M., Serrano M., Fernandez-Piqueras J., and Martin-Caballero J. Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene 25 (2006) 4128-4132
25. Delavaine L., and La Thangue N.B. Control of E2F activity by p21Waf1/Cip1. Oncogene 18 (1999) 5381-5392
26. Deng C., Zhang P., Harper J.W., Elledge S.J., and Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82 (1995) 675-684
27. Denicourt C., Saenz C.C., Datnow B., Cui X.S., and Dowdy S.F. Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res. 67 (2007) 9238-9243
28. Devgan V., Mammucari C., Millar S.E., Brisken C., and Dotto G.P. p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev. 19 (2005) 1485-1495
29. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., and Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27 (2001) 222-224
30. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
31. Estanyol J.M., Jaumot M., Casanovas O., Rodriguez-Vilarrupla A., Agell N., and Bachs O. The protein SET regulates the inhibitory effect of p21(Cip1) on cyclin E-cyclin-dependent kinase 2 activity. J. Biol. Chem. 274 (1999) 33161-33165
32. Esteve V., Canela N., Rodriguez-Vilarrupla A., Aligue R., Agell N., Mingarro I., Bachs O., and Perez-Paya E. The structural plasticity of the C terminus of p21Cip1 is a determinant for target protein recognition. ChemBioChem 4 (2003) 863-869
33. Etienne-Manneville S., and Hall A. Rho GTPases in cell biology. Nature 420 (2002) 629-635
34. Eymin B., and Brambilla E. The yin and the yang of p27Kip1 as a target for cancer therapy. Eur. Respir. J. 23 (2004) 663-664
35. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L.H., Broudy V., Perlmutter R.M., et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85 (1996) 733-744
36. Fero M.L., Randel E., Gurley K.E., Roberts J.M., and Kemp C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396 (1998) 177-180
37. Fitzpatrick G.V., Soloway P.D., and Higgins M.J. Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. Nat. Genet. 32 (2002) 426-431
38. Franklin D.S., Godfrey V.L., O'Brien D.A., Deng C., and Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 20 (2000) 6147-6158
39. Frey M.R., Golovin A., and Polk D.B. Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J. Biol. Chem. 279 (2004) 44513-44521
40. Fujita N., Sato S., and Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 278 (2003) 49254-49260
41. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., and Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11 (1997) 2090-2100
42. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafre S.A., and Farace M.G. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282 (2007) 23716-23724
43. Gao H., Ouyang X., Banach-Petrosky W., Borowsky A.D., Lin Y., Kim M., Lee H., Shih W.J., Cardiff R.D., Shen M.M., et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 101 (2004) 17204-17209
44. Gartel A.L., and Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp. Cell Res. 246 (1999) 280-289
45. Geng Y., Yu Q., Sicinska E., Das M., Bronson R.T., and Sicinski P. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc. Natl. Acad. Sci. USA 98 (2001) 194-199
46. Georgia S., Soliz R., Li M., Zhang P., and Bhushan A. p57 and Hes1 coordinate cell cycle exit with self-renewal of pancreatic progenitors. Dev. Biol. 298 (2006) 22-31
47. Georgitsi M., Raitila A., Karhu A., van der Luijt R.B., Aalfs C.M., Sane T., Vierimaa O., Makinen M.J., Tuppurainen K., Paschke R., et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92 (2007) 3321-3325
48. Gosselet F.P., Magnaldo T., Culerrier R.M., Sarasin A., and Ehrhart J.C. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes. Cell. Signal. 19 (2007) 731-739
49. Grimmler M., Wang Y., Mund T., Cilensek Z., Keidel E.M., Waddell M.B., Jakel H., Kullmann M., Kriwacki R.W., and Hengst L. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128 (2007) 269-280
50. Gu Y., Turck C.W., and Morgan D.O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366 (1993) 707-710
51. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
52. Hatada I., Nabetani A., Morisaki H., Xin Z., Ohishi S., Tonoki H., Niikawa N., Inoue M., Komoto Y., Okada A., et al. New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Hum. Genet. 100 (1997) 681-683
53. Higashimoto K., Soejima H., Saito T., Okumura K., and Mukai T. Imprinting disruption of the CDKN1C/KCNQ1OT1 domain: the molecular mechanisms causing Beckwith-Wiedemann syndrome and cancer. Cytogenet. Genome Res. 113 (2006) 306-312
54. Kip1 degradation through its regulation of cyclin E/CDK2 activity. J. Biol. Chem. 274 (1999) 3396-3401
55. Huang S., Shu L., Dilling M.B., Easton J., Harwood F.C., Ichijo H., and Houghton P.J. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol. Cell 11 (2003) 1491-1501
56. Itoh Y., Masuyama N., Nakayama K., Nakayama K.I., and Gotoh Y. The cyclin-dependent kinase inhibitors p57 and p27 regulate neuronal migration in the developing mouse neocortex. J. Biol. Chem. 282 (2007) 390-396
57. James M.K., Ray A., Leznova D., and Blain S.W. Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol. Cell. Biol. 28 (2008) 498-510 10.1128/MCB.02171-06 Published online October 1, 2007
58. Jones D.L., Alani R.M., and Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11 (1997) 2101-2111
59. Kardinal C., Dangers M., Kardinal A., Koch A., Brandt D.T., Tamura T., and Welte K. Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 107 (2006) 1133-1140
60. Kawauchi T., Chihama K., Nabeshima Y., and Hoshino M. Cdk5 phosphorylates and stabilizes p27kip1 contributing to actin organization and cortical neuronal migration. Nat. Cell Biol. 8 (2006) 17-26
61. Kikuchi T., Toyota M., Itoh F., Suzuki H., Obata T., Yamamoto H., Kakiuchi H., Kusano M., Issa J.P., Tokino T., et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 21 (2002) 2741-2749
62. Kitaura H., Shinshi M., Uchikoshi Y., Ono T., Iguchi-Ariga S.M., and Ariga H. Reciprocal regulation via protein-protein interaction between c-Myc and p21(cip1/waf1/sdi1) in DNA replication and transcription. J. Biol. Chem. 275 (2000) 10477-10483
63. Kiyokawa H., Kineman R.D., Manova-Todorova K.O., Soares V.C., Hoffman E.S., Ono M., Khanam D., Hayday A.C., Frohman L.A., and Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85 (1996) 721-732
64. Kobatake T., Yano M., Toyooka S., Tsukuda K., Dote H., Kikuchi T., Toyota M., Ouchida M., Aoe M., Date H., et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol. Rep. 12 (2004) 1087-1092
65. Kondo M., Matsuoka S., Uchida K., Osada H., Nagatake M., Takagi K., Harper J.W., Takahashi T., and Elledge S.J. Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene 12 (1996) 1365-1368
66. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., and Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11 (1997) 847-862
67. Lacy E.R., Filippov I., Lewis W.S., Otieno S., Xiao L., Weiss S., Hengst L., and Kriwacki R.W. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat. Struct. Mol. Biol. 11 (2004) 358-364
68. Lai S., Goepfert H., Gillenwater A.M., Luna M.A., and El-Naggar A.K. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma. Clin. Cancer Res. 6 (2000) 3172-3176
69. le Sage C., Nagel R., Egan D.A., Schrier M., Mesman E., Mangiola A., Anile C., Maira G., Mercatelli N., Ciafre S.A., et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26 (2007) 3699-3708
70. Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/Cofilin pathway. J. Biol. Chem. 279 (2003) 1885-1891
71. Lee M.H., Reynisdottir I., and Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9 (1995) 639-649
72. Lee M.P., DeBaun M., Randhawa G., Reichard B.A., Elledge S.J., and Feinberg A.P. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am. J. Hum. Genet. 61 (1997) 304-309
73. Levkau B., Koyama H., Raines E.W., Clurman B.E., Herren B., Orth K., Roberts J.M., and Ross R. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol. Cell 1 (1998) 553-563
74. Li Z., Jiao X., Wang C., Ju X., Lu Y., Yuan L., Lisanti M.P., Katiyar S., and Pestell R.G. Cyclin D1 induction of cellular migration requires p27KIP1. Cancer Res. 66 (2006) 9986-9994
75. Liang J., Zubovitch J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.H., Ciarallo S., Catzavelos C., Beniston R., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8 (2002) 1153-1160
76. Liu Y., Yeh N., Zhu X.H., Leversha M., Cordon-Cardo C., Ghossein R., Singh B., Holland E., and Koff A. Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J. 26 (2007) 4683-4693
77. Luo Y., Hurwitz J., and Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375 (1995) 159-161
78. Malumbres M., Ortega S., and Barbacid M. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol. Chem. 381 (2000) 827-838
79. Martin-Caballero J., Flores J.M., Garcia-Palencia P., and Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 61 (2001) 6234-6238
80. Martin-Caballero J., Flores J.M., Garcia-Palencia P., Collado M., and Serrano M. Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice. Oncogene 23 (2004) 8231-8237
81. Martin P. Wound healing-aiming for perfect skin regeneration. Science 276 (1997) 75-81
82. Matsuoka S., Edwards M.C., Bai C., Parker S., Zhang P., Baldini A., Harper J.W., and Elledge S.J. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9 (1995) 650-662
83. Matsuoka S., Thompson J.S., Edwards M.C., Bartletta J.M., Grundy P., Kalikin L.M., Harper J.W., Elledge S.J., and Feinberg A.P. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc. Natl. Acad. Sci. USA 93 (1996) 3026-3030
84. kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol. Cell. Biol. 23 (2003) 216-228
85. Muraoka R.S., Lenferink A.E., Law B., Hamilton E., Brantley D.M., Roebuck L.R., and Arteaga C.L. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22 (2002) 2204-2219
86. Kip1 induces cell migration. Nat. Med. 4 (1998) 1449-1452
87. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D.Y., and Nakayama K. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 (1996) 707-720
88. Nallamshetty S., Crook M., Boehm M., Yoshimoto T., Olive M., and Nabel E.G. The cell cycle regulator p27Kip1 interacts with MCM7, a DNA replication licensing factor, to inhibit initiation of DNA replication. FEBS Lett. 579 (2005) 6529-6536
89. Nance J., and Priess J.R. Cell polarity and gastrulation in C. elegans. Development 129 (2002) 387-397
90. Nguyen L., Besson A., Heng J., Schurrmans C., Teboul L., Philpott A., Roberts J.M., and Guillemot F. p27Kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev. 20 (2006) 1511-1524
91. Nobes C.D., and Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol. 144 (1999) 1235-1244
92. O'Keefe D., Dao D., Zhao L., Sanderson R., Warburton D., Weiss L., Anyane-Yeboa K., and Tycko B. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am. J. Hum. Genet. 61 (1997) 295-303
93. Oh H., Mammucari C., Nenci A., Cabodi S., Cohen S.N., and Dotto G.P. Negative regulation of cell growth and differentiation by TSG101 through association with p21(Cip1/WAF1). Proc. Natl. Acad. Sci. USA 99 (2002) 5430-5435
94. Waf1/Cip1. Nature 394 (1998) 295-299
95. Ono T., Kitaura H., Ugai H., Murata T., Yokoyama K.K., Iguchi-Ariga S.M., and Ariga H. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. J. Biol. Chem. 275 (2000) 31145-31154
96. Ophascharoensuk V., Fero M.L., Hughes J., Roberts J.M., and Shankland S.J. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat. Med. 4 (1998) 575-580
97. Papakonstanti E.A., Ridley A.J., and Vanhaesebroeck B. The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J. 26 (2007) 3050-3061
98. Park M.S., Rosai J., Nguyen H.T., Capodieci P., Cordon-Cardo C., and Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc. Natl. Acad. Sci. USA 96 (1999) 6382-6387
99. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., Fend F., Graw J., and Atkinson M.J. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA 103 (2006) 15558-15563
100. Perez-Roger I., Kim S.H., Griffiths B., Sewing A., and Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 18 (1999) 5310-5320
101. Perris R. The extracellular matrix in neural crest-cell migration. Trends Neurosci. 20 (1997) 23-31
102. Polyak K., Kato J., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., and Koff A. p27Kip1, a cyclin-CDK inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes Dev. 8 (1994) 9-22
103. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 (1994) 59-66
104. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 55 (1995) 1211-1214
105. Qi C.F., Xiang S., Shin M.S., Hao X., Lee C.H., Zhou J.X., Torrey T.A., Hartley J.W., Fredrickson T.N., and Morse III H.C. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B-cell lymphomas. Leuk. Res. 30 (2006) 153-163
106. Ren X.D., Kiosses W.B., Sieg D.J., Otey C.A., Schlaepfer D.D., and Schwartz M.A. Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover. J. Cell Sci. 113 (2000) 3673-3678
107. Reynaud E.G., Leibovitch M.P., Tintignac L.A., Pelpel K., Guillier M., and Leibovitch S.A. Stabilization of MyoD by direct binding to p57(Kip2). J. Biol. Chem. 275 (2000) 18767-18776
108. Reynisdottir I., Polyak K., Iavarone A., and Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9 (1995) 1831-1845
109. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., and Horwitz A.F. Cell migration: integrating signals from front to back. Science 302 (2003) 1704-1709
110. Rodier G., Montaglioni A., Di Marcotullio L., Coulombe P., Draetta G.F., Pagano M., and Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser 10 and is not a prerequisite for its proteolysis. EMBO J. 20 (2001) 6672-6682
111. Rodriguez-Vilarrupla A., Jaumot M., Abella N., Canela N., Brun S., Diaz C., Estanyol J.M., Bachs O., and Agell N. Binding of calmodulin to the carboxy-terminal region of p21 induces nuclear accumulation via inhibition of protein kinase C-mediated phosphorylation of Ser153. Mol. Cell. Biol. 25 (2005) 7364-7374
112. Waf1/Cip1/Sdi1: association with cell senescence and tumour promoting activities of stromal fibroblasts. Cancer Lett. 179 (2002) 1-14
113. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res. 63 (2003) 2705-2715
114. Rosen D.G., Yang G., Cai K.Q., Bast R.C., Gershenson D.M., Silva E.G., and Liu J. Subcellular localization of p27Kip1 expression predicts poor prognosis in human ovarian cancer. Clin. Cancer Res. 11 (2005) 632-637
115. Kip1 cyclin dependent kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382 (1996) 325-331
116. Sahai E., and Marshall C.J. Differing modes of tumor cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 5 (2003) 711-719
117. Sahai E., Olson M.F., and Marshall C.J. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 20 (2001) 755-766
118. Sekimoto T., Fukumoto M., and Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J. 23 (2004) 1934-1942
119. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
120. Shim J., Lee H., Park J., Kim H., and Choi E.J. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381 (1996) 804-806
121. Shimada Y., Gulli M.P., and Peter M. Nuclear sequestration of the exchange factor Cdc24 by Far1 regulates cell polarity during yeast mating. Nat. Cell Biol. 2 (2000) 117-124
122. Slingerland J., and Pagano M. Regulation of the CDK inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183 (2000) 10-17
123. Snowden A.W., Anderson L.A., Webster G.A., and Perkins N.D. A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation. Mol. Cell. Biol. 20 (2000) 2676-2686
124. St Croix B., Florenes V.A., Rak J.W., Flanagan M., Bhattacharya N., Slingerland J.M., and Kerbel R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2 (1996) 1204-1210
125. Suzuki A., Tsutomi Y., Akahane K., Araki T., and Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17 (1998) 931-939
126. Cip1/Waf1 regulates neurite remodeling by inhibiting Rho-kinase activity. J. Cell Biol. 158 (2002) 321-329
127. Tanaka H., Yamashita T., Yachi K., Fujiwara T., Yoshikawa H., and Tohyama M. Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 127 (2004) 155-164
128. Toyoshima H., and Hunter T. p27, a novel inhibitor of G1 cyclin-CDK protein kinase activity, is related to p21. Cell 78 (1994) 67-74
129. Vaccarello G., Figliola R., Cramerotti S., Novelli F., and Maione R. p57Kip2 is induced by MyoD through a p73-dependent pathway. J. Mol. Biol. 356 (2006) 578-588
130. Vernon A.E., Devine C., and Philpott A. The cdk inhibitor p27Xic1 is required for differentiation of primary neurones in Xenopus. Development 130 (2003) 85-92
131. Vial E., Sahai E., and Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4 (2003) 67-79
132. V12-induced transformation in a manner dependent on p27 status. J. Biol. Chem. 277 (2002) 16433-16440
133. Vlachos P., Nyman U., Hajji N., and Joseph B. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ. 14 (2007) 1497-1507
134. Wang Y.A., Elson A., and Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc. Natl. Acad. Sci. USA 94 (1997) 14590-14595
135. Watanabe H., Pan Z.Q., Schreiber-Agus N., DePinho R.A., Hurwitz J., and Xiong Y. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. USA 95 (1998) 1392-1397
136. Weksberg R., Shuman C., and Smith A.C. Beckwith-Wiedemann syndrome. Am. J. Med. Genet. C. Semin. Med. Genet. 137 (2005) 12-23
137. Worthylake R.A., Lemoine S., Watson J.M., and Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J. Cell Biol. 154 (2001) 147-160
138. Wu F.Y., Wang S.E., Sanders M.E., Shin I., Rojo F., Baselga J., and Arteaga C.L. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 66 (2006) 2162-2172
139. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
140. Yan Y., Frisen J., Lee M.H., Massague J., and Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 11 (1997) 973-983
141. Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J. Biol. Chem. 278 (2003) 52919-52923
142. Zhang P., Liegeois N.J., Wong C., Finegold M., Hou H., Thompson J.C., Silverman A., Harper J.W., DePinho R.A., and Elledge S.J. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387 (1997) 151-158
143. Cip1/Waf1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252